Shares of Agenus Inc. (AGEN) are surging more than 25% Tuesday morning after the company granted exclusive global license to Bristol-Myers Squibb Company (BMY) for Agenus' anti-TIGIT bispecific antibody Program, AGEN1777.
Agenus will receive a $200 million upfront payment and up to $1.36 billion, on achieving milestones, in addition to tiered double-digit royalties on net product sales.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com